Acta Chimica and Pharmaceutica Indica
ISSN: 2277-288X

Cancer Immunotherapy Scholarly Journal

Cancer immunotherapy (treatment that utilizes a person's framework to battle disease) has become a significant field of oncology. There are four key sorts of safe treatments: mono-clonal antibodies; disease immunizations; check point inhibitors; and vague malignant growth invulnerable (treatments that don't target disease explicitly, however invigorate insusceptible cells that can cause hostile to malignant growth safe response , like interleukins, cytokines, between ferons, and others). Tumors express ligands to safe checkpoint proteins, for example, PD-1 (customized cell demise 1) and CTLA-4 (cytotoxic T-lymphocyte-related protein 4), intervening square of insusceptible reaction. Subsequently, the advancement of inhibitors of these safe checkpoint pathways is a promising region of resistant therapeutics. What's more, tumors express tumor antigens that can be focused with antibodies; counter acting agent medicate conjugates; fanciful antigen receptor (CAR) T cells; or by different methodologies. Dendritic cell vaccination is extra noteworthy immunotherapy technique close to malignant growth. This Special Issue is centered around ongoing immunotherapy draws near, novel resistant therapeutics, and immunology flagging pathways in malignant growth.  

High Impact List of Articles

Relevant Topics in Chemistry

Awards Nomination

Table of Contents

Google Scholar citation report
Citations : 858

Acta Chimica and Pharmaceutica Indica received 858 citations as per Google Scholar report

Citation image

Indexed In

  • Open J Gate
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Cosmos IF
  • Scientific Indexing Services (SIS)
  • ICMJE

View More

For Authors

For Librarians

Flyer

Open Access Journals